These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27436386)

  • 1. Rifaximin combined with polymyxins: A potential regimen for selective decontamination of multidrug-resistant bacteria in the digestive tract?
    Betts JW; Phee LM; Wareham DW
    J Glob Antimicrob Resist; 2016 Mar; 4():11-15. PubMed ID: 27436386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.
    Daneman N; Sarwar S; Fowler RA; Cuthbertson BH;
    Lancet Infect Dis; 2013 Apr; 13(4):328-41. PubMed ID: 23352693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The added value of the selective SuperPolymyxin™ medium in detecting rectal carriage of Gram-negative bacteria with acquired colistin resistance in intensive care unit patients receiving selective digestive decontamination.
    van Hout D; Janssen AB; Rentenaar RJ; Vlooswijk JPM; Boel CHE; Bonten MJM
    Eur J Clin Microbiol Infect Dis; 2020 Feb; 39(2):265-271. PubMed ID: 31691864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carriage of antibiotic-resistant Gram-negative bacteria after discontinuation of selective decontamination of the digestive tract (SDD) or selective oropharyngeal decontamination (SOD).
    de Jonge E; de Wilde RBP; Juffermans NP; Oostdijk EAN; Bernards AT; van Essen EHR; Kuijper EJ; Visser CE; Kesecioglu J; Bonten MJM
    Crit Care; 2018 Sep; 22(1):243. PubMed ID: 30268133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
    Alhanout K; Brunel JM; Raoult D; Rolain JM
    J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
    Hornsey M; Phee L; Stubbings W; Wareham DW
    Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria.
    Wang Y; Feng J; Yu J; Wen L; Chen L; An H; Xiao W; Zhang B; Feng H; Zhou M; Jiang Z
    Ann Clin Microbiol Antimicrob; 2024 Jul; 23(1):60. PubMed ID: 38965559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective decontamination of the oropharynx and the digestive tract, and antimicrobial resistance: a 4 year ecological study in 38 intensive care units in the Netherlands.
    Houben AJ; Oostdijk EA; van der Voort PH; Monen JC; Bonten MJ; van der Bij AK;
    J Antimicrob Chemother; 2014 Mar; 69(3):797-804. PubMed ID: 24144922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin.
    Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
    Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
    Brown P; Dawson MJ
    J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
    Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
    Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
    Menegucci TC; Albiero J; Migliorini LB; Alves JL; Viana GF; Mazucheli J; Carrara-Marroni FE; Cardoso CL; Tognim MC
    Int J Antimicrob Agents; 2016 May; 47(5):380-5. PubMed ID: 27068675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
    Falagas ME; Kasiakou SK
    Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
    Ramos JM; Vidal I; Bellot P; Gómez-Hurtado I; Zapater P; Such J
    Gut; 2016 Jan; 65(1):182-3. PubMed ID: 25832107
    [No Abstract]   [Full Text] [Related]  

  • 18. Bacteriological data on a prospective multicenter study of the effect of two different regimens for selective decontamination in patients with acute leukaemia.
    van der Waaij D; Gaus W; Krieger D; Linzenmeier G; Rozenberg-Arska M; de Vries-Hospers HG
    Infection; 1986; 14(6):268-74. PubMed ID: 3028964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.
    Rey-Jurado E; Tudó G; de la Bellacasa JP; Espasa M; González-Martín J
    Int J Antimicrob Agents; 2013 Mar; 41(3):278-80. PubMed ID: 23312604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit.
    Al Naiemi N; Heddema ER; Bart A; de Jonge E; Vandenbroucke-Grauls CM; Savelkoul PH; Duim B
    J Antimicrob Chemother; 2006 Oct; 58(4):853-6. PubMed ID: 16891326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.